local_hospital

Centre Hospitalier De Brive

Address
1 Boulevard Du Docteur Verlhac, 19100 Brive La Gaillarde, France

Centre Hospitalier De Brive - Critical Care and Infectious Disease Research

Centre Hospitalier De Brive is an active clinical research institution focusing on critical care medicine and infectious diseases. The center demonstrates particular expertise in managing complex infections and life-threatening conditions requiring intensive care unit support, with a strong emphasis on innovative therapeutic approaches and antimicrobial stewardship.

  • Catheter-related bloodstream infections and novel antibiotic therapies for Staphylococcus aureus
  • Septic shock management and cardiac dysfunction in critically ill patients
  • ICU-acquired immunosuppression and prevention of secondary infections
  • Chronic Myeloid Leukemia treatment optimization and tyrosine kinase inhibitor discontinuation strategies

The center's research portfolio demonstrates a comprehensive approach to critical illness, investigating both antimicrobial treatment strategies for catheter-related infections and hemodynamic support in septic cardiomyopathy. Additionally, the facility is advancing knowledge in immune system modulation among ICU patients with sustained immunosuppression, while also contributing to hematological oncology through studies on treatment de-escalation in chronic myeloid leukemia patients achieving sustained remission.

Site Overview

assignment
7
connected trials
corporate_fare
5
sponsors
science
44
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
7
Total trials linked
Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 2 of 4 therapeutic areas and 15 of 44 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 44 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
5
Sponsors (total)
5
Active sponsors
4

Sponsor Network

Top 4 by active trials.

lock +3 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 978 other sites in France

description
Trial volume
7
Outperforms 69% of sites
public
Therapeutic diversity
5areas
Outperforms 73% of sites
groups
Sponsor diversity
5sponsors
Outperforms 67% of sites

Therapeutic Area Benchmark — France

Select a therapeutic area to compare against other sites in France.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: France

Market Share

Country: France

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Centre Hospitalier De Brive

lock Showing 1 of 7 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants with Sepsis-associated Acute Kidney Injury (SERENIA)AstraZeneca ABPhase IIRecruitingMar 2026

IMP list

lock Showing 1 of 44 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Amoxicillin Sodium2Unknown2023-06-232023-06-23

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.